Disease-modifying pharmacological approaches to correcting basal forebrain cholinergic neuronal (BFCN) dysfunction and degeneration
Neuropsychopharmacology
.
2022 Jan;47(1):405-406.
doi: 10.1038/s41386-021-01135-x.
Authors
John J Alam
1
,
Ralph A Nixon
2
3
4
Affiliations
1
EIP Pharma Inc, Boston, MA, USA. jalam@eippharma.com.
2
The Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA.
3
Departments of Psychiatry and Cell Biology, NYU Langone Medical Center, New York, NY, USA.
4
NYU Neuroscience Institute, New York University, New York, NY, USA.
PMID:
34389810
PMCID:
PMC8616925
DOI:
10.1038/s41386-021-01135-x
No abstract available
Publication types
News
Research Support, N.I.H., Extramural
MeSH terms
Alzheimer Disease*
Basal Forebrain*
Cholinergic Agents
Cholinergic Neurons
Humans
Substances
Cholinergic Agents
Grants and funding
R01 AG062376/AG/NIA NIH HHS/United States
P01 AG017617/AG/NIA NIH HHS/United States